title: TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma.
abstract: Interferon-gamma-inducible protein 10 is a potent chemoattractant for natural killer cells and activated T lymphocytes. It also displays angiostatic properties and some antitumor activity. Tumor necrosis factor-alpha (TNF-alpha) is a powerful immunomodulating cytokine with demonstrated tumoricidal activity in various tumor models and the ability to induce strong immune responses. This prompted us to evaluate the antitumor effects of recombinant parvoviruses designed to deliver IP-10 or TNF-alpha into a glioblastoma. When Gl261 murine glioma cells were infected in vitro with an IP-10- or TNF-alpha-transducing parvoviral vector and were subcutaneously implanted in mice, tumor growth was significantly delayed. Complete tumor regression was observed when the glioma cells were coinfected with both the vectors, demonstrating synergistic antitumor activity. In an established in vivo glioma model, however, repeated simultaneous peritumoral injection of the IP-10- and TNF-alpha-delivering parvoviruses failed to improve the therapeutic effect as compared with the use of a single cytokine-delivering vector. In this tumor model, cytokine-mediated immunostimulation, rather than inhibition of vascularization, is likely responsible for the therapeutic efficacy.
authors.affiliation: Deutsches Krebsforschungszentrum, Infection and Cancer Program, Heidelberg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Enderlin
authors.forename: E V
authors.initials: EV
authors.lastname: Kleinmann
authors.forename: S
authors.initials: S
authors.lastname: Struyf
authors.forename: C
authors.initials: C
authors.lastname: Buracchi
authors.forename: A
authors.initials: A
authors.lastname: Vecchi
authors.forename: R
authors.initials: R
authors.lastname: Kinscherf
authors.forename: F
authors.initials: F
authors.lastname: Kiessling
authors.forename: S
authors.initials: S
authors.lastname: Paschek
authors.forename: S
authors.initials: S
authors.lastname: Sozzani
authors.forename: J
authors.initials: J
authors.lastname: Rommelaere
authors.forename: J J
authors.initials: JJ
authors.lastname: Cornelis
authors.forename: J
authors.initials: J
authors.lastname: Van Damme
authors.forename: C
authors.initials: C
authors.lastname: Dinsart
mesh_terms: D000818:Animals; D054357:Chemokine CXCL10 / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000166:cytology / Q000821:virology; D004357:Drug Synergism; D005260:Female; D005822:Genetic Vectors; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000821:virology; D052661:H-1 parvovirus / Q000502:physiology; D006801:Humans; D007121:Immunocompetence; D051379:Mice; D008810:Mice, Inbred C57BL; D008915:Minute Virus of Mice / Q000502:physiology; D009336:Necrosis / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use*
chemical_list: C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D014409:Tumor Necrosis Factor-alpha